



Promoting More Conservative Prescribing

Gordon D. Schiff; William L. Galanter

JAMA. 2009;301(8):865-867 (doi:10.1001/jama.2009.195)

Online article and related content
current as of March 12, 2009.

<http://jama.ama-assn.org/cgi/content/full/301/8/865>

Correction	Contact me if this article is corrected.
Citations	Contact me when this article is cited.
Topic collections	Medical Practice; Medical Education; Quality of Care; Quality of Care, Other; Drug Therapy; Drug Therapy, Other Contact me when new articles are published in these topic areas.
CME course	Online CME course available.
CME course	Online CME course available.

Subscribe
<http://jama.com/subscribe>

Permissions
permissions@ama-assn.org
<http://pubs.ama-assn.org/misc/permissions.dtl>

Email Alerts
<http://jamaarchives.com/alerts>

Reprints/E-prints
reprints@ama-assn.org

Promoting More Conservative Prescribing

Gordon D. Schiff, MD

William L. Galanter, MD, PhD

ALTHOUGH MEDICAL AND PHARMACY CURRICULA and journals are rich with information about drugs and treatment of specific diseases, there is a paucity of education on ways to become effective lifetime prescribers. Two recent reports from the Association of American Medical Colleges (AAMC) lamented the current state of pharmacology teaching¹ and the disturbing extent of pharmaceutical industry influence at all stages of medical education.² Given the well-documented prevalence of medication-related harm and inappropriate prescribing,^{3,4} such educational reform is necessary but not sufficient to ensure that patients are optimally treated. Beyond improved training in pharmacology and minimization of unbalanced industry-sponsored education, trainees need guiding principles to inform their thinking about pharmacotherapy to help them become more careful, cautious, evidence-based prescribers.

In this Commentary, we offer 25 such principles (BOX), making no claims that they represent the definitive or comprehensive antidote to the many factors contributing to suboptimal prescribing. However, based on our experience educating physicians, pharmacists, and medical students, we believe these lessons are fundamental for teaching clinicians how to develop excellent prescribing skills, yet such fundamentals are absent or underemphasized in current medical and pharmacy education.

The AAMC report emphasized expanded teaching about “factors that make each patient unique,” pharmacology and pharmacokinetics, optimal dosing, prescribing regulations, drug interactions and adverse reactions, and use of drug compendia and informational resources.¹ However, prescribers also need to be taught a set of skills and attitudes that will help them approach claims for drugs, especially new drugs, more critically. Although the AAMC document discusses the need for a number of patient monitoring and communication functions embodied in these conservative prescribing principles, without a more cautious and, frankly,

more skeptical approach to using drugs, prescribers will lack the will and the skills to resist ubiquitous promotional messages encouraging them to reach for newer and often more expensive medications.

Such skepticism needs to be grounded in historical and current lessons that offer reasons for precaution. Lessons from iatrogenic events related to agents such as thalidomide, phen-fen, or rofecoxib (Vioxx); recognition that new medications are tested in limited numbers of patients with few comorbidities, typically for a relatively short time; and disquieting revelations that promotional activities distort what prescribers learn about drugs⁵ are lessons worth learning and incorporating into prescribing decision making. Although the attitudes and behaviors recommended in our principles should not be terribly controversial, taken together they represent a departure from current practice. If prescribers routinely heeded these principles, many patients could be spared the risk or expense of needless or harmful drug therapy.

Principles for More Conservative Prescribing

Think Beyond Drugs. More than learning to “just say no” to drugs, clinicians require confidence, time, evidence, and readily available options for alternate ways of helping patients. These include physical therapy, exercise, diet changes, counseling, stress reduction techniques, or even surgery where appropriate. Placing more emphasis on prevention will lead to a greater return for clinicians’ investment of time and resources.

Practice More Strategic Prescribing. Smarter approaches to initiation, selection, and changing drug regimens are needed. Too often clinicians reflexively prescribe for each symptom a patient experiences. Although operational aspects of the principles in this category need to be more rigorously studied and individualized for each patient, problem, drug, and indication, the need for more judicious prescribing practices is obvious.

Heightened Vigilance Regarding Adverse Effects. Studies show that the adverse effects of many drugs are either

Author Affiliations: Division of General Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (Dr Schiff); and Departments of Medicine and Pharmacy Practice, University of Illinois at Chicago, Chicago (Dr Galanter).

Corresponding Author: Gordon D. Schiff, MD, Center for Patient Safety Research and Practice, Division of General Medicine, 1620 Tremont, Third Floor, General Medicine, Boston, MA 02120 (gschiff@partners.org).

 CME available online at www.jamaarchivescme.com and questions on p 891.

Box. Principles of Conservative Prescribing**Think Beyond Drugs**

Seek nondrug alternatives as first rather than last resort
 Treat underlying causes rather than solely treating symptoms
 Look for prevention opportunities rather than exclusively focusing on established disease or symptom amelioration

More Strategic Prescribing

Defer immediate drug treatment whenever possible and desirable
 Use only a few drugs; learn to use them well
 Avoid drug switching without compelling evidence-based reasons
 Be skeptical about “individualizing” therapy when trials suggest little evidence of benefit in the studied cohort
 Be cautious about telephone or e-mail prescribing
 Whenever possible, start only 1 new drug at a time

Heightened Adverse Effects Vigilance

Maintain a high index of suspicion for adverse drug effects
 Educate patients about potential adverse effects to ensure more timely recognition
 Be alert to clues of drug withdrawal symptoms masquerading as disease “relapses”

Caution and Skepticism Regarding New Drugs

Learn about new drugs and new indications from unbiased sources and from colleagues with reputations for conservative prescribing

Do not rush to use new drugs, for new adverse effects often emerge later

Be certain drugs improve clinical outcomes rather than solely modify a surrogate marker

Do not stretch indications away from trial-based evidence
 Avoid seduction by elegant pharmacology or physiological mechanisms in the absence of demonstrated clinical outcomes benefit

Beware of selective reporting or presentation of studies

Shared Agenda With Patients

Do not reflexively succumb to patients' requests for new drugs they have heard advertised or recommended

Avoid prescribing additional drugs for “refractory” problems, failing to appreciate possible nonadherence

Obtain accurate medication histories to avoid repeat prescriptions for drugs previously tried unsuccessfully

Discontinue drugs not working or no longer needed

Work with and promote patients' desires for conservative therapy

Weigh Long-term, Broader Impacts

Think beyond short-term effects; consider longer-term benefits and risks

Seek better prescribing systems (computerized physician order entry, reliable laboratory monitoring) rather than just new drugs as ways to improve pharmacotherapy

entirely overlooked or their recognition is delayed—both in individual patients⁶ and in populations using the drug.⁷ Patients need to be better educated in anticipating problems, and signals of potential adverse effects need to be addressed in more scientific and timely ways. Closer linkage between macro-level epidemiological pharmacovigilance and personal clinician vigilance needs to occur.

Caution and Skepticism Regarding New Drugs. New drugs often appear to be safer—a deceptive impression resulting from more limited experience with their use. Only when more adequate types and numbers of patients are studied for sufficiently long periods can a more accurate profile of their risks and benefits emerge. Although many payers stress prescribing generic medications for cost savings, another important value of generics is the greater safety knowledge inherent in their longer track record compared with more newly marketed brand name products.⁷ When using new drugs, prescribing should be more limited and should target patients, indications, and situations for which benefit has been demonstrated.

Shared Agenda With Patients. Much excessive prescribing is attributed to patients' demands for drugs—demands driven by direct-to-consumer advertising⁸ or expectations for

medications such as antibiotics, sleep medications, or analgesics. Prescribers need to learn new approaches, deploying aikido-like tactics, skillfully leveraging them to redirect rather than simply refuse such requests. Thus, in lieu of blanket refusals and administrative barriers and in lieu of the imposition of arbitrary and often unfair formulary tiers and co-pays, more thoughtful clinical approaches to rationalizing utilization are needed. These should involve patients directly based on their personal medication experiences, accurate drug histories, trust built on realistic expectations, and a shared desire to use only the minimum number of drugs necessary.

Weigh Longer-term, Broader Effects. Drugs can provide short-term benefits, but often their long-term effects are suboptimal or unknown. For example, treating obesity or onychomycosis with drugs can be quite effective in the short term, but long-term results are often disappointing.^{9,10} Ecological effects of antibiotics are obviously important considerations, but the environmental effects of other pharmaceutical chemicals is also an emerging issue.¹¹ To achieve safer, more effective prescribing practices requires more than the mere development of new chemical entities or the restraining of the prescribers' pens—it also requires efforts to make prescribing systems safer.¹²

Countervailing Factors— Barriers to Conservative Prescribing

Despite their apparent simplicity and logic, implementing these prescribing principles is not easy. Understanding and overcoming barriers is critical. Practicing clinicians face tremendous time pressures—the ease of writing a prescription compared with pursuing alternative approaches cannot be overestimated. Specialist physicians feel compelled to prescribe newer drugs because many referred patients report failing more conservative therapies, and a specialist physician's reputation is seemingly enhanced by using the latest treatment advances. Advocates of more aggressive control of risk factors for cardiac and other chronic diseases are now tying physicians' payments to their performance in overcoming "clinical inertia," a concept that conservative approaches superficially resemble. Meanwhile with income bonuses linked to patient satisfaction ratings, why risk disappointing patients who request a medication they had seen advertised? Patients who have unresponsive or incurable conditions cling to hopes raised by so-called promising studies, often appealing to their physicians for a chance to try new drugs.

The published medical literature is a minefield deterring conservative prescribing. Various factors mitigate a balanced picture of risks and benefits. From well-documented biases that arise in industry-funded and designed studies that dominate therapeutic research to more subtle publication biases (negative trials are less newsworthy) that also work against conservative prescribing conclusions,¹³ there are relatively few funded advocates or breakthrough studies urging a conservative course. Even ethical patient protections such as early stopping rules—which can tilt toward early study termination at a time significant benefit is demonstrated but perhaps before sufficient time for rarer adverse outcomes emerge—or ethical qualms in withholding active drug treatment for a control group all lean away from conservative findings and lessons.

Conclusions

Considered in isolation, none of these conservative prescribing principles is particularly novel. But taken together they represent a significant shift in current prescribing patterns. Medical therapy for many acute and chronic diseases and their risk factors has come to be dominated by aggressive treatment approaches. From diabetes to rheumatoid arthritis, from mental disorders to heart failure, a philosophy of "newer and more is better" has replaced one that stresses "fewer and more time-tested is best." These principles aim to restore a balance between these 2 philosophies, recognizing that as guiding principles, they should

be flexibly interpreted in response to specific therapies, individual clinical circumstances, and local organizational factors.

From Osler¹⁴ to leading pharmacology textbooks, taking a more skeptical and conservative approach to pharmacotherapy has a long and honorable history in medicine. These principles extend the AAMC recommendations in urging more cautious and judicious drug use. Rather than therapeutic nihilism, the approach of these guidelines aims to better respect the limitations of knowledge and more closely align clinicians with the interests of patients.

Financial Disclosures: Dr Galanter reports being a paid consultant of the Walgreens Health Initiative formulary committee. Dr Schiff reports no financial conflicts.

Funding/Support: This work originated in the Formulary Leveraged Improved Prescribing (FLIP) project, which was funded by the Attorney General Consumer and Prescriber Education Grant Program, and was supported by grant U18HS016973 from the Agency for Healthcare Research and Quality.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.

Additional Contributions: We thank Bruce Lambert, PhD, Department of Pharmacy Administration, University of Illinois at Chicago, and members of the FLIP project team for contributing to the 25 principles.

REFERENCES

1. Association of American Medical Colleges. *Contemporary Issues in Medicine: Education in Safe and Effective Prescribing Practices*. Washington, DC: Association of American Medical Colleges; July 2008.
2. Association of American Medical Colleges. *Industry Funding of Medical Education: Report of an AAMC Task Force*. Washington, DC: Association of American Medical Colleges; June 2008.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*. 1998;279(15):1200-1205.
4. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. *JAMA*. 2001;286(22):2823-2829.
5. Waxman HA. The lessons of Vioxx—drug safety and sales. *N Engl J Med*. 2005;352(25):2576-2578.
6. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. *N Engl J Med*. 2003;348(16):1556-1564.
7. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. *JAMA*. 2002;287(17):2215-2220.
8. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. *JAMA*. 2005;293(16):1995-2002.
9. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. *Lancet*. 2007;369(9555):71-77.
10. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. *Arch Dermatol*. 2002;138(3):353-357.
11. Jones OA, Voulvoulis N, Lester JN. Potential ecological and human health risks associated with the presence of pharmaceutically active compounds in the aquatic environment. *Crit Rev Toxicol*. 2004;34(4):335-350.
12. Schiff GD, Klass D, Peterson J, Shah G, Bates DW. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. *Arch Intern Med*. 2003;163(8):893-900.
13. DeAngelis CD, Drazen JM, Frizelle FA, et al; International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *JAMA*. 2004;292(11):1363-1364.
14. Macht DI. Osler's prescriptions and materia medica. *Osler Libr Newsl*. 1994;(76):1-5.